[Form 4] Virios Therapeutics, Inc. Common Stock Insider Trading Activity

Rhea-AI Filing Summary

First US Bancshares, Inc. (FUSB) – Form 4 insider filing: Director David Peter Hale reported the acquisition of 655.38 phantom stock units on 30 June 2025 under the company’s Non-Employee Directors’ Deferred Compensation Plan. The units convert to common stock on a 1-for-1 basis and include 93.29 dividend-equivalent shares. Following the transaction, Hale directly holds 18,477.14 phantom units. The filing indicates routine deferred-compensation accrual rather than an open-market purchase, suggesting limited immediate market impact but continued alignment of the director’s interests with shareholders.

Insights

Securities Analyst

TL;DR: Routine deferred-comp plan grant; neutral impact.

The A-coded transaction reflects automatic crediting of phantom stock units, not a discretionary purchase. Because these units settle at the end of a deferral period and carry no voting rights until conversion, the event does not signal a valuation view or change float. Hale’s post-transaction total of 18.5k units represents modest equity exposure relative to FUSB’s 6.1 million outstanding shares, so dilution and signalling effects are negligible. Overall, the filing is compliance-driven and immaterial to the investment thesis.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grosswald Ralph

(Last) (First) (Middle)

C/O DOGWOOD THERAPEUTICS, INC.

44 MILTON AVENUE

(Street)

ALPHARETTA GA 30009

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Dogwood Therapeutics, Inc. [ DWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP OF OPERATIONS

3. Date of Earliest Transaction (Month/Day/Year)
06/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.71	06/27/2025		A		12,075		(1)	06/27/2035	Common Stock	12,075	$0	12,075	D

Explanation of Responses:

1. The stock option vests one-third on June 27, 2026 and 1/24th monthly thereafter.

	/s/ Greg Duncan, Attorney-in-Fact	07/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What securities did Director David P. Hale acquire in the 30 Jun 2025 transaction for FUSB?

He acquired 655.38 phantom stock units that will convert to common shares on a 1-for-1 basis.

How many FUSB phantom stock units does Hale own after the reported transaction?

After the credit, Hale beneficially owns 18,477.14 phantom stock units.

Was the acquisition an open-market purchase?

No. The units were accrued under the Deferred Compensation Plan, not bought in the market.

Do the phantom stock units include dividend equivalents?

Yes, the total includes 93.29 shares attributable to quarterly dividends reinvested under the plan.

Will the phantom stock units be settled in cash or stock?

They are to be settled in common stock at the end of the deferral period.